Human bone disorders: Pathological role and diagnostic potential of matrix metalloproteinases

International Journal of Biochemistry and Cell Biology

Volumn 42, Issue 10, 2010, Pages 1590-1593

  Galliera, E ^a   Banfi, G ^a   Corsi, M M ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Bone disorders; Bone remodeling; Diagnostic biomarkers; Matrix metalloproteinases

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; STROMELYSIN;

ANKYLOSING SPONDYLITIS; BONE MARROW; BONE REMODELING; FRACTURE; FRACTURE HEALING; HUMAN; OSSIFICATION; OSTEOARTHRITIS; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SHORT SURVEY;

BIOLOGICAL MARKERS; BONE DISEASES; BONE REMODELING; BONE RESORPTION; DISEASE PROGRESSION; HUMANS; MATRIX METALLOPROTEINASES; PROGNOSIS;

EID: 77956187501     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2010.06.015     Document Type: Short Survey

References (30)

1. Alexandrakis M.G., Sfiridaki A., Miyakis S., Pappa C., Kandidaki E., Alegakis A., et al. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma. Clin Chim Acta 2007, 379:31-35.
2. Bolton C.E., Stone M.D., Edwards P.H., Duckers J.M., Evans W.D., Shale D.J. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Chron Respir Dis 2009, 6:81-87.
3. Burrage P.S., Brinckerhoff C.E. Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 2007, 8:293-303.
4. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.
5. Fregnani E.R., Sobral L.M., Alves F.A., Soares F.A., Kowalski L.P., Coletta R.D. Presence of myofibroblasts and expression of matrix metalloproteinase-2 (mmp-2) in ameloblastomas correlate with rupture of the osseous cortical. Pathol Oncol Res 2009, 15:231-240.
6. Garnero P., Thompson E., Woodworth T., Smolen J.S. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010, 62:33-43.
7. Karsenty G., Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002, 2:389-406.
8. Krane S.M., Inada M. Matrix metalloproteinases and bone. Bone 2008, 43:7-18.
9. Logar D.B., Komadina R., Prezelj J., Ostanek B., Trost Z., Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J Bone Miner Metab 2007, 25:219-225.
10. Lohmander L.S., Brandt K.D., Mazzuca S.A., Katz B.P., Larsson S., Struglics A., et al. Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 2005, 52:3160-3167.
11. Luo X.H., Guo L.J., Shan P.F., Xie H., Wu X.P., Zhang H., et al. Relationship of circulating mmp-2, mmp-1, and timp-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women. Osteoporos Int 2006, 17:521-526.
12. Mandal M., Mandal A., Das S., Chakraborti T., Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003, 252:305-329.
13. Martignetti J.A., Aqeel A.A., Sewairi W.A., Boumah C.E., Kambouris M., Mayouf S.A., et al. Mutation of the matrix metalloproteinase 2 gene (mmp2) causes a multicentric osteolysis and arthritis syndrome. Nat Genet 2001, 28:261-265.
14. Murphy G., Lee M.H. What are the roles of metalloproteinases in cartilage and bone damage?. Ann Rheum Dis 2005, 64(Suppl. 4):iv44-iv47.
15. Naka T., Kuester D., Boltze C., Schulz T.O., Samii A., Herold C., et al. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin b; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Hum Pathol 2008, 39:217-223.
16. Nomura T., Ishii A., Shimizu H., Taguchi N., Yoshie H., Kusakari H., et al. Tissue inhibitor of metalloproteinases-1, matrix metalloproteinases-1 and -8, and collagenase activity levels in peri-implant crevicular fluid after implantation. Clin Oral Implants Res 2000, 11:430-440.
17. Ortega N., Behonick D., Stickens D., Werb Z. How proteases regulate bone morphogenesis. Ann N Y Acad Sci 2003, 995:109-116.
18. Page-McCaw A., Ewald A.J., Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007, 8:221-233.
19. Pasternak B., Aspenberg P. Metalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics. Acta Orthop 2009, 80:693-703.
20. Reinhardt R.A., Lee H.M., Schmid M., Payne J.B., Golub L. Relationship between gelatinases and bone turnover in the healing bone defect. J Oral Maxillofac Surg 2005, 63:1455-1460.
21. Rengel Y., Ospelt C., Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007, 9:221.
22. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
23. Schiltz C., Marty C., de Vernejoul M.C., Geoffroy V. Inhibition of osteoblastic metalloproteinases in mice prevents bone loss induced by oestrogen deficiency. J Cell Biochem 2008, 104:1803-1817.
24. Sorsa T., Mantyla P., Ronka H., Kallio P., Kallis G.B., Lundqvist C., et al. Scientific basis of a matrix metalloproteinase-8 specific chair-side test for monitoring periodontal and peri-implant health and disease. Ann N Y Acad Sci 1999, 878:130-140.
25. 2 laser: a fluorescence microscopy study. Int J Oral Maxillofac Implants 2005, 20:203-210.
26. Teronen O., Heikkila P., Konttinen Y.T., Laitinen M., Salo T., Hanemaaijer R., et al. Mmp inhibition and downregulation by bisphosphonates. Ann N Y Acad Sci 1999, 878:453-465.
27. Tuysuz B., Mosig R., Altun G., Sancak S., Glucksman M.J., Martignetti J.A. A novel matrix metalloproteinase 2 (mmp2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects. Eur J Hum Genet 2009, 17:565-572.
28. Visvanathan S., Marini J.C., Smolen J.S., Clair E.W., Pritchard C., Shergy W., et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 2007, 34:1465-1474.
29. Wendling D. Bone loss in ankylosing spondylitis: can we put the puzzle together?. J Rheumatol 2005, 32:1184-1185.
30. Wendling D., Toussirot E. Bone and matrix remodeling markers: a new tool for assessment of treatment efficacy in ankylosing spondylitis?. J Rheumatol 2007, 34:1647-1649.